Clinical Trial Search

Primary: Objective Response Rate (ORR) for Participants With Measurable Metastatic Castration-resistant Prostate Cancer (mCRPC) and Breast Cancer Gene (BRCA) Mutation — 34.2…

Primary: The Proportion of Subjects Who Achieved ASAS20 Clinical Response — 3; 14 Participants

Primary: Number of Participants Experiencing Adverse Events (AEs) in Part 1 — 5; 5; 1; 4 Participants

Primary: Front Surface Wettability, by Category — 78; 0; 0; 0 eyes

Primary: Time to Successful Placement of a Functioning USGIV/IO — 163.7; 67.3 seconds

Primary: Local Progression-free Survival (LPFS) — 22.30801 months

Primary: The Number of Participants With Non-Fatal DVT, PE, and CVST, and VTE-Related-Death — 31; 45 Participants — p=0.0403

Primary: Time to Regain Birthweight in Infants Who Receive L-carnitine Supplementation Compared to Controls — 8.12; 8.4 days — p=<0.05

Primary: Peripheral Insulin Sensitivity (RD) Measured by the Change in Glucose Rates of Disappearance With Resveratrol or Placebo at Baseline and at 4 Weeks. — 6.573; 7.272…

Primary: Change From Baseline at 9 Weeks in the Desire Subscore of the Female Sexual Function Index ("Sexual Desire") — 0.64; 0.60; 0.62 units on a scale — p=0.46

Primary: Number of Participants With Adverse Events (Day 29) — 96; 17; 68; 17 Participants

Primary: Period 1: Absolute Bioavailability Based on Ratio of Dose Normalized Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC∞ ) for TAK-906 — 9.12…

Primary: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) — 7; 2 Participants

Primary: Percentage of Participants With Serious Adverse Events (SAEs) and Serious Adverse Drug Reactions (SADRs) — 0.15; 0.00 percentage of participants

Primary: Change in Hemoglobin (Hb) Concentration Between the Baseline and the Evaluation Period for Each Patient — 11.05; 0.48 grams/deciliter (g/dL)